Clinical Trials Logo

Waldenstrom Macroglobulinemia clinical trials

View clinical trials related to Waldenstrom Macroglobulinemia.

Filter by:

NCT ID: NCT05734495 Recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Start date: May 2, 2023
Phase: Phase 2
Study type: Interventional

This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: - Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) - Venetoclax (a BCL2 inhibitor)

NCT ID: NCT05645744 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Start date: September 29, 2021
Phase:
Study type: Observational

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

NCT ID: NCT05640102 Recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Start date: March 3, 2023
Phase:
Study type: Observational [Patient Registry]

This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.

NCT ID: NCT05602363 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Start date: August 1, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

NCT ID: NCT05565638 Recruiting - Multiple Myeloma Clinical Trials

PROFAST Intervention in Precursor Multiple Myeloma

PROFAST
Start date: March 6, 2023
Phase: N/A
Study type: Interventional

This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and smoldering waldenstrom macroglobulinemia (SWM). The purpose of this study is to understand if fasting for a prolonged period of time during the nighttime hours is a strategy to prevent overweight and obese individuals from developing blood cancer. Participants will be randomized into the following two groups: - Group A: PROFAST intervention for 4 months - Group B: Healthy Lifestyle Control group for 4 months

NCT ID: NCT05544019 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Study of SGR-1505 in Mature B-Cell Neoplasms

Start date: April 10, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

NCT ID: NCT05537766 Recruiting - Clinical trials for Relapsed/Refractory Hairy Cell Leukemia

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

ZUMA-25
Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

Master protocol: The goal of this master clinical study is to test how well the study drug, brexucabtagene autoleucel, works in participants with rare B-cell malignancies: relapsed/refractory Waldenstrom macroglobulinemia (r/r WM) (Substudy A - no longer recruiting), relapsed/refractory Richter transformation (r/r RT) (Substudy B), relapsed/refractory Burkitt lymphoma (r/r BL) (Substudy C and relapsed/refractory hairy cell leukemia (r/r HCL) (Substudy D - no longer recruiting).

NCT ID: NCT05360238 Recruiting - Clinical trials for B-cell Lymphoma Refractory

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Start date: May 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Study to Assess the Safety, Tolerability and Efficacy of MB-106 in Patients with Relapsed or Refractory B-Cell NHL or CLL

NCT ID: NCT05326308 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

ARIADNE
Start date: April 26, 2022
Phase:
Study type: Observational

The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.

NCT ID: NCT05294731 Recruiting - Clinical trials for Mantle Cell Lymphoma

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Start date: March 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts